New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2013
07:02 EDTTFXTeleflex sees FY13 adjusted EPS $4.70-$4.90, consensus $4.83
Sees constant currency revenue growth between 11% and 13%, consensus $1.73B.
News For TFX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
07:03 EDTTFXTeleflex affirms FY15 adjusted EPS view of $6.10-$6.35, consensus $6.24
The company continues to estimate that constant currency revenue growth will be between 4%-6%. On a GAAP basis, revenues are expected to be flat to down 2% versus the prior year due to the unfavorable impact of foreign currency fluctuations.
07:01 EDTTFXTeleflex reports Q2 adjusted EPS $1.42, consensus $1.42
Subscribe for More Information
July 29, 2015
18:01 EDTTFXTeleflex signs new agreement with HealthTrust
Teleflex has announced a new group purchasing agreement with HealthTrust covering Teleflex Incorporated’s Weck EFx Portfolio of Port Closure products. The agreement becomes effective August 1. Weck EFx Port Closure Products from Teleflex are designed to allow surgeons to provide fast, safe closure of laparoscopic port sites with a range of options that suit their procedural and institutional needs. The new Weck EFx Shield™ Fascial Closure System is the only shielded port closure device, providing enhanced sharps protection for safe, uniform, and consistent fascial closure, and is designed with: A unique shielded wing for enhanced sharps protection; Intuitive wing deployment; An innovative fascial closure technique with unassisted suture retrieval.
17:33 EDTTFXTeleflex announces Arrow Endurance receives FDA market clearance
Subscribe for More Information
17:06 EDTTFXTeleflex acquires assets of N. Stenning & Co Ltd.
Teleflex has acquired certain assets of N. Stenning & Co Ltd. Pty, its distribution partner for Teleflex’s surgical products in Australia. Included in the transaction are the N. Stenning surgical customer relationships throughout Australia and a team of surgical sales representatives who are now direct employees of Teleflex Australia.
07:20 EDTTFXTeleflex reports study results of Arrowg+ard technology effectiveness
Teleflex Incorporated announced that newly published research has further documented the ability of the company’s ARROW Central Venous Catheter with ARROWg+ard Blue Technology to reduce both catheter-related bloodstream infections and direct costs associated with treating those infections, even when the infection risk is already low. The peer‐reviewed retrospective study examined CVC usage in the subclavian insertion site. That location has been shown to be associated with lower overall infection risk, compared to the jugular and femoral infection sites.2 The study appears online in the respected American Journal of Infection Control, which is published by APIC, the Association for Professionals in Infection Control and Epidemiology. The antimicrobial catheter with ARROWg+ard Blue Technology outperformed an unprotected CVC in both infection reduction and total cost per patient. Within the study, the protected catheter achieved a zero infection rate of 0/1,000 catheter days. In contrast, the unprotected device was associated with a higher CRBSI rate of 2.12/1,000 catheter days. The results were statistically significant. The antimicrobial, protected catheter was also associated with prolonged CRBSI-free time compared to the unprotected catheter, including dwell times of up to 30 days without a bloodstream infection.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use